Interview with Francisco Piccolo, President, Biogen Idec Brazil
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Brasil Produtos
Farmacêuticos Ltda.
Edifício Olimpia Trade
Av. Dr. Cardoso de Melo, 1.184,
17º andar,
Vila Olimpia- São Paulo-SP,
CEP; 04548-004
Brazil
Phone: +55 11 3568 3400
Fax: +55 11 3568 3440
www.biogenidec.com.br
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Jaime Rabi, director of Microbiológica, documents the unique development path of the company and its pioneering contribution to the production of antiretroviral medicines in Brazil, as well as its international…
Heraldo Marchezini, CEO of the Brazilian biotech company Biomm and one of the leading executives in the Brazilian biopharmaceutical sector, provides insights into the eye-catching international partnerships recently signed by…
Marco Fireman, vice-minister and chairman of the National Commission for the Incorporation of Technologies (CONITEC); a board that advises the Brazilian Ministry of Health on the inclusion of new health…
Samuel Mauricio, vice-president for Brazil at Octapharma, one of the largest human protein manufacturers in the world, provides an insightful analysis of the Brazilian plasma market, demonstrating Octapharma’s remarkable willingness…
Nelson Mussolini, executive president of the syndicate of the pharmaceutical industry in the State of Sao Paulo (Sindusfarma), which represents around 95 percent of all pharmaceutical marketing in the country…
Antonio Britto, the executive president of Interfarma, the main association gathering together local and international innovators in Brazil, provides insights into some of the hottest topics in Brazil’s pharmaceutical sector,…
Eduardo Martins, president director of Pharlab, provides insights into the “2020 vision” that has been driving the eye-catching development of this ambitious domestic company and documents how Pharlab is leveraging…
Nilton Paletta, President Latin America at IQVIA™ and responsible for the company’s operations in 18 countries in the region, provides insights into the most impactful dynamics shaping the Brazilian pharmaceutical…
Guilherme Maradei, managing director of Merck Brazil and general manager Biopharma, documents the eye-catching growth that the Brazilian affiliate has been experiencing over the past two years and provides insights…
Alexandre França, CEO of Aspen Pharma Brazil, describes the transformation of the Brazilian organization over the past year, which allowed Aspen Brazil to establish itself as the best performing affiliate…
Marlene Oliveira, founder and president of the Instituto Lado a Lado Pela Vida (Side by Side for Life) documents the main objectives and achievements of this Brazilian institution of reference,…
Luciano Finardi, general manager of Celgene Brazil, describes the unrivalled commitment of the company to Brazilian patients and documents the remarkable dedication of Celgene to registering its flagship product in…
See our Cookie Privacy Policy Here
